192 related articles for article (PubMed ID: 31625415)
1. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
Hari P; Ung B; Abouzaid S; Agarwal A; Parikh K
Future Oncol; 2019 Dec; 15(35):4045-4056. PubMed ID: 31625415
[No Abstract] [Full Text] [Related]
2. Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.
Uyl-de Groot CA; Ramsden R; Lee D; Boersma J; Zweegman S; Dhanasiri S
Eur J Haematol; 2020 Nov; 105(5):635-645. PubMed ID: 32705720
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Baertsch MA; Mai EK; Hielscher T; Bertsch U; Salwender HJ; Munder M; Fuhrmann S; Dührsen U; Brossart P; Neben K; Schlenzka J; Kunz C; Raab MS; Hillengaß J; Jauch A; Seckinger A; Hose D; Luntz S; Sonneveld P; Lokhorst H; Martin H; Goerner M; Hoffmann M; Lindemann HW; Bernhard H; Blau IW; Scheid C; Besemer B; Weisel KC; Hänel M; Dürig J; Goldschmidt H;
Blood Cancer J; 2021 Jan; 11(1):1. PubMed ID: 33414374
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
Leukemia; 2018 Mar; 32(3):712-718. PubMed ID: 28848227
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
6. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
7. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.
Amsler IG; Jeker B; Mansouri Taleghani B; Bacher U; Betticher D; Egger T; Zander T; Luethi JM; Novak U; Pabst T
Leuk Lymphoma; 2019 Feb; 60(2):511-514. PubMed ID: 30616438
[No Abstract] [Full Text] [Related]
8. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F; Louzada M
Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
10. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R
Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443
[TBL] [Abstract][Full Text] [Related]
11. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P
Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560
[TBL] [Abstract][Full Text] [Related]
12. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.
Pasvolsky O; Milton DR; Rauf M; Tanner MR; Bashir Q; Srour S; Tang G; Saini N; Ramdial J; Masood A; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Nov; 28(11):752.e1-752.e6. PubMed ID: 35940528
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
15. Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I; Gertz M
Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
[TBL] [Abstract][Full Text] [Related]
19. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy.
Wudhikarn K; Padrnos L; Lasho T; LaPlant B; Kumar S; Dispenzieri A; Lacy M; Rajkumar SV; Gertz M; Mangaonkar AA; Gonsalves W; Ketterling R; Shi CX; Fonseca R; Stewart AK; Patnaik MM
Am J Hematol; 2021 May; 96(5):E157-E162. PubMed ID: 33580975
[No Abstract] [Full Text] [Related]
20. Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.
Sharma N; Chen DT; Zhao Q; Williams NY; Rosko A; Benson DM; Chaudhry M; Bumma N; Khan A; Devarakonda S; Hofmeister CC; Sborov D; Efebera YA
Biol Blood Marrow Transplant; 2020 Jan; 26(1):44-49. PubMed ID: 31518644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]